Ovarian cancer

• An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting
  2024-517432-21-00 4 2025-05-30 "Gynecological Cancers"
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra … Recruiting
  2023-509598-22-01 6 2025-05-13 "Oncology - Breast cancer"
• A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors Recruiting
  2024-512019-36-00 1 2025-04-09 "Adrenocortical carcinoma"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• A study to learn more about how well treatment with sevabertinib (BAY2927088) tablets works and how safe it is in participants who have a so … Recruiting
  2024-517419-62-00 4 2025-02-28 "HER2 mutation"
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 "Recurrent or Metastatic Solid Tumors (endometrial cancer (EC"
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 "BRCA wild-type advanced ovarian, fallopian tube and primitiv"
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 "Advanced PRAME Positive Cancers"
• A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, pha … Recruiting
  2022-501910-79-01 7 2024-09-18
• N-PLUS Recruiting
  2022-502559-69-01 4 2024-07-04 "advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIG"
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 "Platinum-resistant, high-grade serous ovarian cancer (OVC),h"
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 "Locally Advanced or Metastatic Solid Tumors Harboring a TP53"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
• Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced … Recruiting
  2024-517363-24-00 4 2024-02-16 "Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid"
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 "Breast Cancer; Advanced solid tumors including but not limit"
• An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/ … Recruiting
  2024-513006-61-00 3 2023-08-23 "Advanced and/or metastatic solid tumours (colorectal cancer,"
• Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer. BICOV-1 (Bidirectional Chemoth … Recruiting
  2022-502691-23-00 6 2023-02-27
• An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OA … Recruiting
  2024-510836-31-00 1 2023-02-14 "Advanced and/or metastatic solid tumours (colorectal cancer,"
• Study of AZD9574 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies Recruiting
  2023-504984-17-00 7 2022-10-05 "Module 3: advanced/relapsed HER2-negative breast, ovarian, p"
• Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with … Recruiting
  2024-511780-28-00 4 2022-05-05 "Patients with presumed and previously untreated advanced sta"
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 "Advanced ovarian, tubal or peritoneal cancer."
• EXTENSION STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLAXOSMITHKLINE/TESARO-SPONSORED NIRAPARIB STUDY AND ARE JUDGED BY THE INVESTIGATOR … Recruiting
  2023-506618-29-00 4 2021-09-22 "Advanced ovarian, breast, or prostate cancer"
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 "BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian can"
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors Recruiting
  2023-508469-34-00 1 2020-10-14 "Esophageal cancer"

Showing 25–48 of 82 trials